Cliff Asness's BMRN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 5.93 M shares of BioMarin Pharmaceutical Inc. (BMRN) worth $321.28 M, representing 0.21% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2025, adding 2.65 M shares. Largest reduction occurred in Q1 2016, reducing 174,705 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Cliff Asness
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2012 | +116,141 | Add 0.00% | 116,140 | $49.25 |
| Q2 2013 | +14,801 | Add 0.00% | 14,800 | $55.81 |
| Q3 2013 | +2,600 | Add 17.57% | 17,400 | $72.24 |
| Q4 2013 | +62,771 | Add 360.75% | 80,171 | $70.27 |
| Q1 2014 | -55,600 | Reduce 69.35% | 24,571 | $68.21 |
| Q2 2014 | +73,300 | Add 298.32% | 97,871 | $62.21 |
| Q3 2014 | -57,300 | Reduce 58.55% | 40,571 | $72.17 |
| Q4 2014 | -36,477 | Reduce 89.91% | 4,094 | $90.38 |
| Q1 2015 | +32,400 | Add 791.40% | 36,494 | $124.62 |
| Q2 2015 | +274,190 | Add 751.33% | 310,684 | $136.78 |
| Q3 2015 | -92,080 | Reduce 29.64% | 218,604 | $105.32 |
| Q4 2015 | -33,306 | Reduce 15.24% | 185,298 | $104.76 |
| Q1 2016 | -174,705 | Reduce 94.28% | 10,593 | $82.51 |
| Q2 2016 | -10,593 | Sold Out | 10,593 | $0.00 |
| Q3 2016 | +12,718 | New Buy | 12,718 | $92.55 |
| Q4 2016 | -12,718 | Sold Out | 12,718 | $0.00 |
| Q4 2019 | +14,994 | New Buy | 14,994 | $84.23 |
| Q1 2020 | -7,789 | Reduce 51.95% | 7,205 | $82.58 |
| Q2 2020 | +6,850 | Add 95.07% | 14,055 | $123.23 |
| Q3 2020 | +93,421 | Add 664.68% | 107,476 | $76.08 |
| Q4 2020 | -76,861 | Reduce 71.51% | 30,615 | $85.84 |
| Q1 2021 | -23,264 | Reduce 75.99% | 7,351 | $75.50 |
| Q2 2021 | +3,001 | Add 40.82% | 10,352 | $83.08 |
| Q3 2021 | -6,997 | Reduce 67.59% | 3,355 | $77.20 |
| Q4 2021 | -1,054 | Reduce 31.42% | 2,301 | $88.22 |
| Q1 2022 | +3,809 | Add 165.54% | 6,110 | $77.09 |
| Q2 2022 | +1,939 | Add 31.73% | 8,049 | $82.37 |
| Q3 2022 | +21,038 | Add 261.37% | 29,087 | $84.78 |
| Q4 2022 | +21,108 | Add 72.57% | 50,195 | $101.59 |
| Q1 2023 | +25,505 | Add 50.81% | 75,700 | $96.46 |
| Q2 2023 | +99,686 | Add 131.69% | 175,386 | $86.68 |
| Q3 2023 | -86,329 | Reduce 49.22% | 89,057 | $88.48 |
| Q4 2023 | -31,984 | Reduce 35.91% | 57,073 | $96.42 |
| Q1 2024 | -34,410 | Reduce 60.29% | 22,663 | $87.34 |
| Q2 2024 | +32,709 | Add 144.33% | 55,372 | $82.33 |
| Q3 2024 | +543,128 | Add 980.87% | 598,500 | $70.29 |
| Q4 2024 | +685,099 | Add 114.47% | 1.28 M | $65.73 |
| Q1 2025 | +1.64 M | Add 127.94% | 2.93 M | $69.72 |
| Q2 2025 | +2.65 M | Add 90.74% | 5.58 M | $54.91 |
| Q3 2025 | +351,536 | Add 6.30% | 5.93 M | $54.16 |
Cliff Asness's BioMarin Pharmaceutical Investment FAQs
Cliff Asness first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q4 2012, acquiring 116,140 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held BioMarin Pharmaceutical Inc. (BMRN) for 52 quarters since Q4 2012. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q2 2025, adding 5,580,573 shares worth $306.43 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 5,932,109 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $321.28 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.21% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 5,932,109 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.